An update on the central nervous system manifestations of neurofibromatosis type 1

Keyphrases

• Neurofibromatosis Type I 100%
• Neurofibromatosis Type 1 (NF-1) 100%
• Central Nervous System Manifestations 100%
• Neurofibromin 15%
• Central Nervous System Neoplasms 15%
• RAS-MAPK Pathway 15%
• Tumor 7%
• Central Nervous System 7%
• Telomere Shortening 7%
• Diffuse Glioma 7%
• Neoplasms 7%
• Diagnostic Accuracy 7%
• Autosomal Dominant 7%
• Tumor Protein p53 (TP53) 7%
• Morphological Characteristics 7%
• Hydrocephalus 7%
• Aqueductal Stenosis 7%
• Data Combination 7%
• Oncoprotein 7%
• Tumorigenesis 7%
• Glioma 7%
• Epilepsy 7%
• Central Nervous System Tumors 7%
• Sporadic Tumors 7%
• Neoplastic Disease 7%
• Autism Spectrum Disorder 7%
• Biological Properties 7%
• Astrocytoma 7%
• Pilocytic Astrocytoma 7%
• Non-neoplastic 7%
• Functional Disease 7%
• MEK Inhibitor (MEKi) 7%
• Genetic Disease 7%
• ATRX mutation 7%
• Natural History Study 7%
• Variable Phenotype 7%
• Low-grade Astrocytoma 7%
• Vasculopathy 7%
• High-grade Astrocytoma 7%
• Oncogenic Pathways 7%
• Variable Frequency 7%
• Tuberous Sclerosis Complex 7%
• Macrocephaly 7%
• Attention Deficit 7%
• Structural Disease 7%
• Sustained Activation 7%
• Subependymal Giant Cell Astrocytoma 7%
• Mutation-genetics 7%
• Central Nervous System Diseases 7%
• Protein Products 7%
• Impaired Cognition 7%
• Somatic Genetic Alterations 7%
• BRAF Rearrangement 7%
• Histone 3 Gene 7%

Neuroscience

• Central Nervous System 100%
• Neurofibromatosis Type 1 100%
• Astrocytoma 30%
• Nervous System Tumor 23%
• Carcinogenesis 15%
• Mitogen-Activated Protein Kinase 15%
• Glioma 15%
• Somatics 7%
• Telomere 7%
• Stenosis 7%
• Hydrocephalus 7%
• Gene Mutation 7%
• Vascular Disease 7%
• Attention Deficit Hyperactivity Disorder 7%
• Pilocytic Astrocytoma 7%
• TP53 7%
• Oncoprotein 7%
• MEK Inhibitor 7%
• Central Nervous System Disease 7%
• Histone H3 7%
• Tuberous Sclerosis 7%
• Autism Spectrum Disorder 7%
• Macrocephaly 7%
• Genetics 7%
• Epilepsy 7%